compound of formula i; pharmaceutical composition; method of treating disorders that are related to or affected by inhibition of norepinephrine reuptake, the 5-ht6 receptor or the 5-ht2a receptor; a method of treating a learning disorder, a cognitive disorder, a memory disorder, a personality disorder, a behavioral disorder, a movement disorder, a neurodegenerative disorder, drug withdrawal disorder, sleep, an eating disorder, acute drug toxicity, a cardiovascular disorder, a sexual dysfunction, a gastrointestinal disorder, a genitourinary disorder, a pain disorder, a nervous disorder or a symptom disorder vasomotor; method of treating alzheimer's disease, attention deficit disorder, schizophrenia, parkinson's disease, tardive dyskinesia, ataxia, bradykinesia, paroxysmal dyskinesias, restless leg syndrome, tremor, essential tremor epilepsy, stroke or head trauma; method of treating coronary artery disease, myocardial infarction, transient ischemic attack, angina, atrial fibrillation, p

摘要

COMPOUND OF FORMULA 1; PHARMACEUTICAL COMPOSITION; METHOD OF TREATING DISORDERS THAT ARE RELATED TO OR ARE AFFECTED BY THE INHIBITION OF NOREPINEFRINE RECAPTATION, THE 5-HT ~ 6 ~ RECEPTOR OR THE 5-HT ~ 2A ~ RECEPTOR; METHOD OF TREATING A LEARNING DISORDER, A COGNITIVE DISORDER, A MEMORY DISORDER, A PERSONALITY DISORDER, A BEHAVIORAL DISORDER, A MOVEMENT DISTURBANCE, A DISTURBANCE DISTORTION, A DISTURBANCE DISTORTION SLEEP, FROM A FOOD DISORDER, FROM AN ACUTE DRUG TOXICITY, FROM A CARDIOVASCULAR DISORDER, FROM A SEXUAL DISORDER, FROM A GASTRINTESTINAL DISORDER, FROM A GENITOURINARY DISORDER, FROM A DISORDER OF DISORDER, FROM A DISORDER VASOMOTOR; METHOD OF TREATING ALZHEIMER'S DISEASE, A DISORDER OF ATTENTION DEFICIENCY, SCHIZOPHRENIA, PARKINSON'S DISEASE, LATE DYSKINESIS, BRADYCINESIS, DYSKINESIS, THERAPY, DYSKINESIS, THERAPY , EPILEPSY, APOPLEXY OR TRAUMA IN THE HEAD; METHOD OF TREATMENT OF CORONARY ARTERIAL DISEASE, MYOCARDIAL INFARCTION, TRANSITIONAL ISCHEMIC ATTACK, ANGINA, ATRIAL FIBRILLATION, PLAQUETARY AGGREGATION, IRRIGATION OF THE SIGNS OF CHAIN, STRENGTHENING, GASTRINTESTINAL REFLUX, DYSPEPSIA, URINARY INCONTINENCE BY STRESS OR URINARY INCONTINENCE OF EMERGENCY; DETECTION TREATMENT METHOD, OBSESSIVE COMPULSIVE DISTURBANCE, SUICIDE TREND, ANXIETY DISTURBANCE, BIPOLAR DISTURBANCE, PANIC DISTURBANCE, NICOTINE ABSTINENCE, ABSTANCEMENT, ABSTANCEMENT ABSTINENCE OF AMPHETAMINE, ABSTINENCE OF NARCOTIC DRUGS, INSOMNIA, SLEEP APNEA, NARCOLEPSY, SEASONAL AFFECTIVE DISTURBANCE, IRREQUIET LEG SYNDROME, NURSING OF NURSING OF NURSING OF NURSING OF NURSING OF NURSING ABOUT NERVOUS ANOREXIA, NERVOUS BULIMIA, NIGHT EATING SYNDROME, COMPULSIVE OVERFILLING, CHRONIC FATIGUE SYNDROME, FIBROMYALGIA, PAIN NEUROPATHY, ANTINOCHYTIC PAIN, DEATHOLOGY, DIAGNOSIS NIGHT SWEAT; AND USE OF A COMPOUND. The present invention relates to compounds of Formula 1: which are modulators of the 5-hydroxytryptamine-6 and 5-hydroxytryptamine-2A receptors and which are inhibitors of norepinephrine reabsorption. The compounds of the invention, as well as their pharmaceutical composition, are useful in the treatment of disorders linked to or associated with 5-hydroxytryptamine-6 and 5-hydroxytryptamine-2A receptors, or with the inhibition of norepinephrine reabsorption.